Neuronic and Santa Clara University partner to develop next-gen neurotech for photobiomodulation guided by real-time brain activity
11 mai 2023 12h00 HE
|
Neuronic Devices Operations GmbH
Integrating photobiomodulation with neurofeedback will revolutionize treatment of brain disorders SANTA CLARA, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Neuronic, a multi-national company focused...
SciSparc Completed Treatment of Last Patient Enrolled for its Phase IIa Clinical Trial for Alzheimer's Disease and Agitation
02 mai 2023 07h25 HE
|
SciSparc Ltd
The Company previously announced positive interim results from the trial meeting its primary endpoints TEL AVIV, Israel, May 02, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or...
AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update
28 avr. 2023 07h00 HE
|
AC Immune SA
AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update ACI-24.060 anti-Abeta vaccine showed positive initial safety and immunogenicity in first Alzheimer’s disease...
Athira Pharma Presents New Clinical and Preclinical Data at the American Academy of Neurology (AAN) 2023 Annual Meeting
25 avr. 2023 16h01 HE
|
Athira Pharma, Inc.
Fosgonimeton improves MMSE (mini-mental state evaluation) after six months in a post hoc analysis from the Phase 2 ACT-AD trial in mild-to-moderate Alzheimer’s disease Preclinical findings with...
Vaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimer’s Disease) Study of Pepinemab
25 avr. 2023 08h00 HE
|
Vaccinex, Inc.
Topline data anticipated in mid-2024 SIGNAL-AD builds on promising data from the Phase 2 SIGNAL Study in Huntington’s Disease ROCHESTER, N.Y., April 25, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc....
Brain Health Academy Enrollment is Now Open, First Session Launches May 17
24 avr. 2023 11h05 HE
|
UsAgainstAlzheimer's
Washington, DC, April 24, 2023 (GLOBE NEWSWIRE) -- Following the launch of its highly successful Brain Health Academy in 2022, UsAgainstAlzheimer’s today announced class will be back in session...
Tiziana Life Sciences to File Alzheimer’s IND for Intranasal Foralumab in Q2 2023
20 avr. 2023 07h00 HE
|
Tiziana Life Sciences Ltd.
Application for $3M of non-dilutive funding for Phase 2a Alzheimer’s trial will be submitted in Q2 2023Tiziana guided by FDA Type “B” meeting comments on its scheduled Q2 2023 intranasal foralumab...
Vaccinex New ActivMAb® application published in Nature Communications for Directed Evolution of GPCRs in Mammalian Cells
12 avr. 2023 08h00 HE
|
Vaccinex, Inc.
GPCRs play a key role in many important physiological processes which makes them an important class of drug targets; however, their biophysical properties have made many GPCRs “difficult to drug” New...
New Study: Lowering Dementia Risk Takes Less BrainHQ Training than Expected
11 avr. 2023 08h00 HE
|
Posit Science
SAN FRANCISCO, April 11, 2023 (GLOBE NEWSWIRE) -- Researchers report a relatively small amount of brain training is required to reduce dementia risk in the Body, Brain, Life for Cognitive...
Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting
11 avr. 2023 07h00 HE
|
Athira Pharma, Inc.
Oral presentation to highlight additional clinical data from Phase 2 ACT-AD trial of fosgonimeton in mild-to-moderate Alzheimer’s disease patients including improvements in measures of cognition and...